Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs.

This document discusses the use of radioactive iodine-131 (RAI) therapy for metastatic well-differentiated thyroid cancer (mDTC) and the importance of individualized dosimetry in nuclear oncology. The authors propose a methodology for estimating the radiation-absorbed dose of RAI based on PET imaging and standard uptake value (SUV) measurements. They suggest that this approach can guide the selection of the appropriate amount of radioactivity to administer to patients with multiple metastatic lesions. The document also highlights the potential application of this dosimetry approach to other types of radiopharmaceutical therapy for solid tumors, such as thyroid cancer, neuroendocrine tumors (NETs), and prostate cancer. The authors emphasize the importance of individualized dosimetry in these therapies to maximize treatment efficacy while minimizing normal organ toxicity. They propose the use of biomarkers and statistical approaches to determine the optimal amount of radioactivity to administer to each patient. The document calls for further research and collaboration among experts in the field to implement true dosimetric approaches in clinical practice. [Extracted from the article]